Literature DB >> 2565588

An alpha 2 adrenoceptor antagonist, Org 3770, enhances nocturnal melatonin secretion in man.

E Palazidou1, A Papadopoulos, A Sitsen, S Stahl, S Checkley.   

Abstract

Nocturnal plasma melatonin concentration was significantly increased in ten normal volunteers following the administration of an alpha 2 adrenoceptor antagonist, Org 3770 (30 mg). This result supports the existence of an alpha 2 adrenergic influence on melatonin secretion in man and provides a possible clinical neuroendocrine marker of the action of an alpha 2 antagonist.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565588     DOI: 10.1007/BF00443424

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Regulation of noradrenaline release in the rat pineal through a negative feedback mechanism mediated by presynaptic alpha-adrenoceptors.

Authors:  F Pelayo; M L Dubocovich; S Z Langer
Journal:  Eur J Pharmacol       Date:  1977-10-01       Impact factor: 4.432

2.  Capillary gas chromatographic assay for the routine monitoring of the antidepressant mepirzepine in human plasma.

Authors:  J E Paanakker; H J van Hal
Journal:  J Chromatogr       Date:  1987-06-05

3.  Direct radioimmunoassay for melatonin in plasma.

Authors:  S Fraser; P Cowen; M Franklin; C Franey; J Arendt
Journal:  Clin Chem       Date:  1983-02       Impact factor: 8.327

4.  Role of the beta adrenergic receptor in the elevation of adenosine cyclic 3',5'-monophosphate and induction of serotonin N-acetyltransferase in rat pineal glands.

Authors:  T Deguchi
Journal:  Mol Pharmacol       Date:  1973-03       Impact factor: 4.436

5.  Pineal N-acetyltransferase and hydroxyindole-O-methyltransferase: control by the retinohypothalamic tract and the suprachiasmatic nucleus.

Authors:  D C Klein; R Y Moore
Journal:  Brain Res       Date:  1979-10-05       Impact factor: 3.252

6.  Effects of a phosphodiesterase inhibitor (Rolipram) on the urinary excretion of 6-sulphatoxy melatonin in man.

Authors:  S A Checkley; F Winton; T Corn; C Franey; J Arendt
Journal:  J Psychopharmacol       Date:  1987-01       Impact factor: 4.153

7.  Hamster and rat pineal gland beta-adrenoceptor characterization with iodocyanopindolol and the effect of decreased catecholamine synthesis on the receptor.

Authors:  C M Craft; W W Morgan; D J Jones; R J Reiter
Journal:  J Pineal Res       Date:  1985       Impact factor: 13.007

8.  Acute treatment with desipramine stimulates melatonin and 6-sulphatoxy melatonin production in man.

Authors:  C Franey; M Aldhous; S Burton; S Checkley; J Arendt
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

9.  Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol.

Authors:  J Arendt; C Bojkowski; C Franey; J Wright; V Marks
Journal:  J Clin Endocrinol Metab       Date:  1985-06       Impact factor: 5.958

10.  Plasma melatonin during desmethylimipramine treatment: evidence for changes in noradrenergic transmission.

Authors:  P J Cowen; A R Green; D G Grahame-Smith; L E Braddock
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

View more
  4 in total

1.  Melatonin, Circadian Rhythms, and Sleep.

Authors:  Irina V. Zhdanova; Valter Tucci
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

2.  Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.

Authors:  D J Skene; C J Bojkowski; J Arendt
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

3.  Melatonin responses to clonidine and yohimbine challenges.

Authors:  S H Kennedy; W Gnam; E Ralevski; G M Brown
Journal:  J Psychiatry Neurosci       Date:  1995-07       Impact factor: 6.186

4.  Neuroimmune endocrine effects of antidepressants.

Authors:  Marco Antonioli; Joanna Rybka; Livia A Carvalho
Journal:  Neuropsychiatr Dis Treat       Date:  2012-02-07       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.